Non-Cochrane · intervention · PM42374337
Comparative efficacy of arthrocentesis combined with different drug injections for arthrogenic temporomandibular disorders: a network meta-analysis of randomized trials.
Wang Dengshun, Wang Yu'e, Gao Tong, et al. · BMC oral health · 2026 · PubMed · doi:10.1186/s12903-026-09013-y
Findings
Population Patients with arthrogenous temporomandibular disorders (internal derangement, disc displacement, osteoarthritis)
197 findings
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.41 [-12.78, 11.96] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.86 [-2.44, 0.71] Low Downgraded: risk of bias, imprecision 2 studies |
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.29 [-1.17, 1.75] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.27 [-0.68, 1.22] Low Downgraded: risk of bias, imprecision 2 studies |
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.82 [-15.82, 17.45] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus glucocorticoid (GCS) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.24 [-15.08, 14.60] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.61 [-8.56, 9.78] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.24 [-8.50, 8.98] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.05 [-1.12, 1.02] Low Downgraded: risk of bias, imprecision 5 studies |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.14 [-8.73, 11.00] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.19 [-0.64, 1.02] Low Downgraded: risk of bias, imprecision 5 studies |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.59 [-4.05, 2.87] Low Downgraded: risk of bias, imprecision 4 studies |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.17 [-0.81, 1.15] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 7.96 [4.92, 11.00] Moderate Downgraded: risk of bias 5 studies |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.08 [-1.02, 0.86] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 8.20 [-6.83, 23.23] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.02 [-11.38, 13.42] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.12 [-1.62, 1.38] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.32 [-14.68, 15.32] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus hyaluronic acid (HA) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.81 [-0.45, 2.08] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.22 [-2.04, 2.48] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.18 [-20.68, 23.04] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.62 [-2.66, 1.41] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.60 [-2.68, 1.48] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.57 [-19.24, 20.37] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.63 [-21.70, 20.44] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.98 [-19.39, 21.34] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.42 [-21.77, 24.61] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.08 [-1.30, 3.47] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.87 [-2.95, 1.22] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.91 [-3.13, 1.31] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.44 [-23.53, 20.64] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.79 [-2.74, 1.15] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.05 [-19.81, 19.72] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.77 [-22.46, 18.93] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.79 [-2.82, 1.25] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.27 [-1.93, 2.47] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus tenoxicam (TX) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -6.78 [-28.70, 15.14] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.91 [-0.19, 2.02] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.33 [-9.57, 14.23] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.60 [0.14, 3.07] Moderate Downgraded: risk of bias 2 studies |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.36 [0.51, 2.21] Moderate Downgraded: risk of bias 3 studies |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.88 [-10.13, 17.90] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.64 [-7.51, 14.79] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.59 [0.66, 2.52] Moderate Downgraded: risk of bias 3 studies |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.61 [-8.99, 16.22] Low Downgraded: risk of bias, imprecision 3 studies |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.85 [-15.62, 23.32] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.74 [-14.43, 19.90] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.45 [0.63, 4.28] Moderate Downgraded: risk of bias Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.09 [-0.18, 2.36] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.62 [-1.21, 2.45] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.82 [-17.21, 22.85] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.50 [-12.39, 17.39] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.19 [-1.58, 5.96] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.64 [-12.87, 20.16] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.64 [0.22, 3.06] Moderate Downgraded: risk of bias 1 study |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.17 [-0.04, 2.38] Low Downgraded: risk of bias, imprecision 1 study |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -4.35 [-17.31, 8.62] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.74 [-0.74, 2.22] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.71 [-13.31, 16.74] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.76 [-21.35, 24.87] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.96 [-0.31, 4.22] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 4.26 [-19.58, 28.10] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.43 [-22.80, 27.66] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.37 [-1.08, 3.82] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus injectable platelet-rich fibrin (iPRF) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.54 [-0.78, 3.85] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.62 [-1.03, 6.27] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 13.46 [-8.64, 35.56] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 5.41 [-17.81, 28.64] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.14 [-2.42, 6.70] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 5.82 [-18.86, 30.50] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 13.70 [-12.86, 40.26] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.33 [-1.49, 6.16] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.87 [-2.71, 6.45] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.45 [-1.07, 5.97] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 4.80 [-16.54, 26.14] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 5.50 [-16.39, 27.39] Low Downgraded: risk of bias, imprecision 1 study |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.95 [-2.54, 6.44] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.24 [-0.78, 7.26] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.74 [-2.19, 7.66] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 4.85 [-24.24, 33.93] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 12.28 [-18.70, 43.26] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.09 [-23.01, 29.18] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 9.85 [-15.60, 35.29] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.71 [-2.11, 5.52] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.78 [-3.87, 5.43] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.90 [-0.01, 1.81] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.24 [-3.13, 7.61] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.02 [0.02, 2.02] Moderate Downgraded: risk of bias 4 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.29 [-2.80, 3.38] Low Downgraded: risk of bias, imprecision 3 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.38 [-0.72, 1.49] Low Downgraded: risk of bias, imprecision 4 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.42 [-5.96, 6.80] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.44 [-0.16, 5.05] Low Downgraded: risk of bias, imprecision 4 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.19 [-8.00, 12.38] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.60 [-12.16, 17.36] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.61 [-1.03, 2.25] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.88 [0.12, 3.64] Moderate Downgraded: risk of bias Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.42 [-15.64, 18.49] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.68 [-12.33, 17.70] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.11 [-1.20, 1.42] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.73 [-0.37, 1.82] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.19 [-0.86, 1.25] Low Downgraded: risk of bias, imprecision 3 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.10 [-9.26, 11.47] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.18 [-5.79, 6.15] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.07 [-0.24, 2.37] Low Downgraded: risk of bias, imprecision 3 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.58 [-8.88, 12.04] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -5.52 [-8.33, -2.70] Moderate Downgraded: risk of bias 3 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.88 [-0.69, 2.44] Low Downgraded: risk of bias, imprecision 2 studies |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.80 [-1.62, 3.21] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.87 [-18.63, 24.36] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.52 [-0.62, 3.66] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.26 [-20.69, 23.21] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.98 [-1.27, 3.23] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.63 [-19.73, 22.98] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.98 [-2.40, 0.44] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.57 [-1.94, 0.79] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.01 [-1.45, 1.42] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 3 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.40 [-13.77, 10.98] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.14 [-15.81, 15.53] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.31 [-4.73, 2.10] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -3.46 [-18.87, 11.94] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus platelet-rich plasma (PRP) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.17 [-14.04, 11.70] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.22 [-20.54, 26.98] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.76 [-6.37, 2.85] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.72 [-5.41, 1.96] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 11.02 [-11.05, 33.09] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.99 [-0.52, 2.50] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.59 [-0.47, 3.65] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 7.25 [-17.01, 31.52] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.99 [-22.90, 28.88] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.40 [-24.20, 31.00] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.30 [-1.11, 3.72] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 7.49 [-20.90, 35.89] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.72 [-0.90, 2.34] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.42 [-0.57, 3.41] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.38 [-22.72, 27.47] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.71 [-24.89, 23.47] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.80 [-0.57, 2.17] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.59 [-0.85, 4.02] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.42 [-29.19, 34.03] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 6.07 [-26.51, 38.66] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.22 [-0.53, 4.96] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.64 [-23.70, 30.98] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.37 [-2.12, 1.38] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.68 [-1.66, 3.02] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.66 [-27.84, 29.16] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus HA and PRP combined | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.42 [-30.52, 35.37] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus HA and PRP combined | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 6.21 [-26.41, 38.82] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus HA and PRP combined | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.15 [-5.84, 3.54] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus microfragmented adipose tissue (FAT) | arthrocentesis plus HA and PRP combined | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.03 [-5.07, 3.01] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.80 [-24.36, 25.95] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 4.81 [-19.37, 28.99] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.61 [-0.75, 1.97] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus HA and PRP combined | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.69 [-1.29, 2.68] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.34 [-25.82, 30.51] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 7.17 [-16.10, 30.44] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 11.76 [-13.91, 37.43] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.14 [-0.15, 2.43] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.04 [-0.14, 4.22] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis alone (placebo) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.75 [-1.85, 7.35] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.75 [-0.71, 4.21] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus glucocorticoid (GCS) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.87 [-0.49, 2.24] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.75 [-26.62, 32.13] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus glucocorticoid (GCS) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 12.00 [-17.59, 41.59] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 6.93 [-14.64, 28.50] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.80 [-21.69, 29.29] Low Downgraded: risk of bias, imprecision 1 study |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.34 [0.30, 6.38] Moderate Downgraded: risk of bias 1 study |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.73 [-24.90, 28.36] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.95 [-0.04, 1.94] Low Downgraded: risk of bias, imprecision 1 study |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus hyaluronic acid (HA) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.87 [-0.08, 3.82] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 10.58 [-23.04, 44.19] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus tenoxicam (TX) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.78 [-31.39, 34.94] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.74 [-0.53, 4.00] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus tenoxicam (TX) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.66 [-0.09, 5.42] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.22 [-1.79, 1.34] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 8.15 [-20.45, 36.74] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.13 [-1.31, 3.57] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.02 [-30.56, 30.59] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 3.29 [-23.88, 30.45] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus injectable platelet-rich fibrin (iPRF) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.15 [-3.69, 5.99] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus microfragmented adipose tissue (FAT) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -3.07 [-37.19, 31.05] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus microfragmented adipose tissue (FAT) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.00 [-5.60, 3.60] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus microfragmented adipose tissue (FAT) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -1.70 [-35.30, 31.90] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus microfragmented adipose tissue (FAT) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.58 [-4.60, 3.44] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.15 [-28.46, 28.76] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 2.46 [-0.95, 5.88] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 1.14 [-1.09, 3.38] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 9.32 [-16.33, 34.96] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 12 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 6.75 [-15.63, 29.13] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus platelet-rich plasma (PRP) | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.76 [-0.69, 2.21] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus HA and PRP combined | Maximum mouth opening (MMO, mm, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD -0.65 [-37.24, 35.95] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus HA and PRP combined | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 4.51 [-30.63, 39.64] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus HA and PRP combined | Pain intensity (VAS rescaled to 0-10, change from baseline) 1 month · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.15 [-1.54, 1.84] Low Downgraded: risk of bias, imprecision Studies not reported |
| arthrocentesis plus bone marrow nucleated cell concentrate (BMNc) | arthrocentesis plus HA and PRP combined | Pain intensity (VAS rescaled to 0-10, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis | MD 0.45 [-2.34, 3.23] Low Downgraded: risk of bias, imprecision Studies not reported |
| Arthrocentesis plus high molecular weight HA (>2 MDa) | arthrocentesis alone (placebo) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis · HA molecular weight (de Campos: low <1 MDa, high >2 MDa) | MD 8.07 [5.00, 11.14] Moderate Downgraded: risk of bias Studies not reported |
| Arthrocentesis plus high molecular weight HA (>2 MDa) | arthrocentesis plus platelet-rich plasma (PRP) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis · HA molecular weight (de Campos: low <1 MDa, high >2 MDa) | MD 5.62 [2.78, 8.45] Moderate Downgraded: risk of bias Studies not reported |
| Arthrocentesis plus low molecular weight HA (<1 MDa) | Placebo or PRP (comparator not specified in text) | Maximum mouth opening (MMO, mm, change from baseline) 6 months · Intra-articular injection after temporomandibular joint arthrocentesis · HA molecular weight (de Campos: low <1 MDa, high >2 MDa) | low-molecular-weight HA showed no difference GRADE not reported Studies not reported |
Included primary studies 19
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Karadayi 2021 Randomised controlled trial of arthrocentesis with or without PRF for internal derangement of the TMJ. PMID:33581954 | 2021 | 4 other reviews | not stated | not extracted yet |
| Comert 2016 Is arthrocentesis plus platelet-rich plasma superior to arthrocentesis plus hyaluronic acid for the treatment of temporomandibular joint… PMID:27364372 | 2016 | 3 other reviews | not stated | not extracted yet |
| Isik 2022 Injectable platelet-rich fibrin as treatment for temporomandibular joint osteoarthritis: A randomized controlled clinical trial. PMID:35798596 | 2022 | 3 other reviews | not stated | not extracted yet |
| Bergstrand 2019 Long-term effectiveness of arthrocentesis with and without hyaluronic acid injection for treatment of temporomandibular joint… PMID:30814387 | 2019 | 2 other reviews | not stated | not extracted yet |
| Comert 2015 Is Arthrocentesis Plus Platelet-Rich Plasma Superior to Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis? A… PMID:25976690 | 2015 | 2 other reviews | not stated | not extracted yet |
| Dasukil 2022 Intra-articular injection of hyaluronic acid versus platelet-rich plasma following single puncture arthrocentesis for the management of… PMID:36372680 | 2022 | 2 other reviews | not stated | not extracted yet |
| Ghoneim 2022 Treatment of temporomandibular joint disc displacement using arthrocentesis combined with injectable platelet rich fibrin versus… PMID:35028072 | 2022 | 2 other reviews | not stated | not extracted yet |
| Isik 2023 Does the Use of Injectable Platelet-Rich Fibrin After Arthrocentesis for Disc Displacement Without Reduction Improve Clinical Outcomes? PMID:36924792 | 2023 | 2 other reviews | not stated | not extracted yet |
| Yapici-Yavuz 2018 A comparison of the effects of Methylprednisolone Acetate, Sodium Hyaluronate and Tenoxicam in the treatment of non-reducing disc… PMID:29680845 | 2018 | 2 other reviews | not stated | not extracted yet |
| Asadpour 2022 Combined Platelet-Rich Plasma and Hyaluronic Acid can Reduce Pain in Patients Undergoing Arthrocentesis for Temporomandibular Joint… PMID:35679902 | 2022 | 1 other review | not stated | not extracted yet |
| De Riu 2019 Bone marrow nucleated cell concentrate autograft in temporomandibular joint degenerative disorders: 1-year results of a randomized… PMID:31601466 | 2019 | 1 other review | not stated | not extracted yet |
| Hegab 2015 Platelet-Rich Plasma Injection as an Effective Treatment for Temporomandibular Joint Osteoarthritis. PMID:25882438 | 2015 | 1 other review | not stated | not extracted yet |
| Jacob 2022 Efficacy of Platelet-Rich Plasma Versus Hyaluronic Acid Following Arthrocentesis for Temporomandibular Joint Disc Disorders: A Randomized… PMID:36896087 | 2022 | 1 other review | not stated | not extracted yet |
| Ozdamar 2017 The impact of arthrocentesis with and without hyaluronic acid injection in the prognosis and synovial fluid myeloperoxidase levels of… PMID:27973684 | 2017 | 1 other review | not stated | not extracted yet |
| Sembronio 2021 Temporomandibular Joint Arthrocentesis and Microfragmented Adipose Tissue Injection for the Treatment of Internal Derangement and… PMID:33675704 | 2021 | 1 other review | not stated | not extracted yet |
| Singh 2021 Evaluation of Arthrocentesis with and Without Platelet-Rich Plasma in the Management of Internal Derangement of Temporomandibular Joint: A… PMID:33927494 | 2021 | 1 other review | not stated | not extracted yet |
| Dharamsi 2024 Use of Sodium Hyaluronate and Triamcinolone Acetonide Following Arthrocentesis in Treatment of Internal Derangement of Temporomandibular… PMID:38312952 | 2024 | this review only | not stated | not extracted yet |
| Hanci 2015 Intra-articular platelet-rich plasma injection for the treatment of temporomandibular disorders and a comparison with arthrocentesis. PMID:25491276 | 2015 | this review only | not stated | not extracted yet |
| Tabrizi 2014 Outcomes of arthrocentesis for the treatment of internal derangement pain: with or without corticosteroids? PMID:25376140 | 2014 | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients with arthrogenous temporomandibular disorders diagnosed by DC/TMD, RDC/TMD or similar criteria, without concurrent conservative treatment | Arthrogenous TMD (internal derangement, disc displacement, osteoarthritis); 783 patients, 819 TMJs (n=19) |
| Intervention | TMJ arthrocentesis followed by injection of PRP, HA, iPRF, BMNc, triamcinolone acetonide or microfragmented adipose tissue | Arthrocentesis plus GCS (dexamethasone, methylprednisolone), HA, tenoxicam, iPRF, PRP, HA+PRP, FAT, BMNc or triamcinolone acetonide (n=19) |
| Comparison | Arthrocentesis irrigation with normal saline or lactated Ringer's solution alone | Arthrocentesis alone (placebo) or active injectable comparator (n=19) |
| Outcomes | Pain intensity (VAS) and maximum mouth opening (MMO); mean difference in change from baseline; MCID 1.4 points for VAS and 5 mm for MMO | Pain VAS and MMO at 1, 3, 6 and 12 months; adverse events reported narratively (12 studies) |
| Study designs | Randomized controlled trials | Randomized controlled trials (n=19) |
| Timing | Follow-up of at least 1 month; analyzed at 1, 3, 6 and 12 months | Follow-up 1 to 12 months; VAS: 12 RCTs at 1 month, 9 at 3 months, 11 at 6 months, 6 at 12 months; MMO: 12, 10, 11 and 6 RCTs |